ARTICLE | Clinical News
Hemolink: Began Phase III trial
September 17, 2001 7:00 AM UTC
Hemosol Inc. (HMSL; TSE:HML), Toronto, Ontario Product: Hemolink Business: Blood products/substitutes Therapeutic category: Blood substitute Target: NA Description: Crosslinked hemoglobin 10% solution...